Combining anti-HPV, anti-p16 and Ki67 immunomarking in the primary diagnosis of OPSCC might be an option for choosing the best approach therapy that seems to exclude extensive surgery at least for advanced cancers. This evidence concerns the gene CDKN2A and cancer.